| 國立成功大學 |
2021-01-12 |
Real-world evidence and optimization of vocal dysfunction in end-stage renal disease patients with secondary hyperparathyroidism
|
Chang;Geng-He;Chou;Fong-Fu;Tsai;Ming-Shao;Tsai;Yao-Te;Yang;Ming-Yu;Huang;Ethan;I;Su;Hui-Chen;Hsu;Cheng-Ming |
| 國立成功大學 |
2023 |
Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease inTaiwan: A Prospective Nationwide Registry (VIOLET) Study
|
Lin, W.-C.;Tai, W.-C.;Chang, Chang C.-H.;Tu, C.-H.;Feng, I.-C.;Shieh, M.-J.;Chung, Chung C.-S.;Yen, H.-H.;Chou, J.-W.;Wong, J.-M.;Liu, Y.-H.;Huang, T.-Y.;Chuang, Chuang C.-H.;Tsai, Tsai T.-J.;Chiang, F.-F.;Lu, C.-Y.;Hsu, W.-H.;Yu, F.-J.;Chao, T.-H.;Wu, D.-C.;Ho, A.-S.;Lin, H.-H.;Feng, C.-L.;Wu, K.-L.;Wong, M.-W.;Tung, C.-C.;Lin, C.-C.;Chen, Chen C.-C.;Hu, Hu H.-M.;Lu, Lu L.-S.;Wang, H.-S.;Wu, I.-C.;Kuo, H.-Y.;Wu, J.-F.;Shih, H.Y.;Ni, Y.-H.;Tang, S.-L.;Chen, P.-H.;Wei, S.-C. |
| 國家衛生研究院 |
2023-05 |
Real-world evidence of hyperbaric oxygen therapy on cardiovascular outcomes in patients with chronic osteomyelitis
|
Tai, CJ;Lu, CK;Lee, CY;Lee, SS;Yang, YH |
| 國立成功大學 |
2021 |
Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study
|
Sato, T.;Cheng, Cheng C.-L.;Park, H.-W.;Kao, Yang Y.-H.;Yang, M.-S.;Fujita, M.;Kumagai, Y.;Tohkin, M.;Saito, Y.;Sai, K. |
| 臺大學術典藏 |
2021-01-28T01:06:14Z |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
Kun-Huei Yeh;Yang T.-S.;Hsu T.-C.;Tzu-Liang Chen W.;Chen H.-H.;Teng H.-W.;Lin B.-W.;Kuan F.-C.;Chiang F.-F.;Duann C.-W.;Li Y.-S.;Lin M.-T.;Fiala-Buskies S.;Ducreux M.;Wang J.-Y.; KUN-HUEI YEH; Yang T.-S.; Hsu T.-C.; Tzu-Liang Chen W.; Chen H.-H.; Teng H.-W.; Lin B.-W.; Kuan F.-C.; Chiang F.-F.; Duann C.-W.; Li Y.-S.; Lin M.-T.; Fiala-Buskies S.; Ducreux M.; Wang J.-Y. |
| 臺大學術典藏 |
2021-01-18T09:12:10Z |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
KUN-HUEI YEH; Yang, Tsai Sheng; Hsu, Tzu Chi; Tzu-Liang Chen, William; Chen, Hong Hwa; Teng, Hao Wei; Lin, Bo Wen; Kuan, Feng Che; Chiang, Feng Fan; Duann, Chi Wei; Li, Ying Shiuan; Lin, Meng Ting; Fiala-Buskies, Sabine; Ducreux, Michel; Wang, Jaw Yuan |
| 國立成功大學 |
2021 |
Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan
|
Yeh, K.-H.;Yang, T.-S.;Hsu, T.-C.;Tzu-Liang, Chen W.;Chen, H.-H.;Teng, H.-W.;Lin, B.-W.;Kuan, F.-C.;Chiang, F.-F.;Duann, C.-W.;Li, Y.-S.;Lin, M.-T.;Fiala-Buskies, S.;Ducreux, M.;Wang, J.-Y. |
| 臺大學術典藏 |
2020-11-11T08:29:15Z |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang C.-C.; Yang C.-C.;Ro L.-S.;Tsai N.-W.;Lin C.-C.;Huang W.-N.;Tsai C.-P.;Lin T.-S.;Jen-Jen Su;Huang C.-C.;Lyu R.-K.;Chen H.-H.;Lee W.-J.;Chen P.-L.;Yang A.; Ro L.-S.; Tsai N.-W.; Lin C.-C.; Huang W.-N.; Tsai C.-P.; Lin T.-S.; JEN-JEN SU; Huang C.-C.; Lyu R.-K.; Chen H.-H.; Lee W.-J.; Chen P.-L.; Yang A. |
| 臺大學術典藏 |
2021-12-02T07:32:18Z |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang C.-C.; Ro L.-S.; Tsai N.-W.; Lin C.-C.; Huang W.-N.; Tsai C.-P.; Lin T.-S.; JEN-JEN SU; Huang C.-C.; Lyu R.-K.; Chen H.-H.; Lee W.-J.; Chen P.-L.; Yang A. |
| 國立成功大學 |
2021 |
Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
|
Yang, C.-C.;Ro, L.-S.;Tsai, N.-W.;Lin, C.-C.;Huang, W.-N.;Tsai, C.-P.;Lin, T.-S.;Su, J.-J.;Huang, C.-C.;Lyu, R.-K.;Chen, H.-H.;Lee, W.-J.;Chen, P.-L.;Yang, A. |
| 國家衛生研究院 |
2020-08-02 |
Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism
|
Chen, TY;Winkelman, JW;Mao, WC;Tzeng, NS;Kuo, TBJ;Yang, CCH;Tsai, HJ;Wu, CS |
| 臺大學術典藏 |
2020-11-04T09:17:05Z |
Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism
|
Chen T.-Y.; Winkelman J.W.; Mao W.-C.; Tzeng N.-S.; Kuo T.B.J.; Yang C.C.H.; Tsai H.-J.; CHI-SHIN WU |
| 臺大學術典藏 |
2018-09-10T18:06:04Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang, S.-K. and Hsieh, M.-S. and Lee, M.-R. and Keng, L.-T. and Ko, J.-C. and Shih, J.-Y.; MENG-RUI LEE; KENG LI-TA; JEN-CHUNG KO; SHENG-KAI LIANG; JIN-YUAN SHIH |
| 臺大學術典藏 |
2020-03-05T08:04:03Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Min-Shu Hsieh;Lee M.-R.;Keng L.-T.;Ko J.-C.;Shih J.-Y.; Liang S.-K.; MIN-SHU HSIEH; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2020-08-13T06:33:37Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Ko J.-C.;Jin-Yuan Shih; Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; JIN-YUAN SHIH |
| 臺大學術典藏 |
2017 |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T03:40:20Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Shih J.-Y.; Ko J.-C.; Lee M.-R.; Keng L.-T.; Hsieh M.-S.; SHENG-KAI LIANG |
| 臺大學術典藏 |
2021-03-11T07:58:31Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-03-11T08:34:21Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Keng L.-T.;Jen-Chang Ko;Shih J.-Y.; SHENG-KAI LIANG; Min-Shu Hsieh; MENG-RUI LEE; LI-TA KENG; JEN-CHANG KO; Jin-Yuan Shih |
| 臺大學術典藏 |
2021-09-17T05:56:07Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-10-04T07:15:44Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y. |
| 臺大學術典藏 |
2021-01-08T02:56:48Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.;Hsieh M.-S.;Lee M.-R.;Li-Ta Keng;Ko J.-C.;Shih J.-Y.; Liang S.-K.; Hsieh M.-S.; Lee M.-R.; LI-TA KENG; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T02:51:01Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
Liang S.-K.; Hsieh M.-S.; MENG-RUI LEE; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
| 臺大學術典藏 |
2021-09-17T03:21:19Z |
Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma
|
SHENG-KAI LIANG; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; Ko J.-C.; Shih J.-Y. |
